Naveen S Vasudev
Overview
Explore the profile of Naveen S Vasudev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frazer R, Arranz J, Estevez S, Parikh O, Krabbe L, Vasudev N, et al.
Curr Oncol Rep
. 2024 Nov;
26(12):1639-1650.
PMID: 39565522
Purpose Of Review: In this review, we discuss which patients with metastatic clear cell renal cell carcinoma (mRCC) may be most suitable for frontline tyrosine kinase inhibitor (TKI) monotherapy, a...
2.
Lee J, Snell E, Brown J, Booth C, Banks R, Turner D, et al.
Genome Res
. 2024 Sep;
34(11):1849-1864.
PMID: 39284687
The use of long-read direct RNA sequencing (DRS) and PCR cDNA sequencing (PCS) in clinical oncology remains limited, with no direct comparison between the two methods. We used DRS and...
3.
Senkin S, Moody S, Diaz-Gay M, Abedi-Ardekani B, Cattiaux T, Ferreiro-Iglesias A, et al.
Nature
. 2024 May;
629(8013):910-918.
PMID: 38693263
International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not yet been identified by conventional epidemiology make a substantial contribution to cancer...
4.
Purdue M, Dutta D, Machiela M, Gorman B, Winter T, Okuhara D, et al.
Nat Genet
. 2024 Apr;
56(5):809-818.
PMID: 38671320
Here, in a multi-ancestry genome-wide association study meta-analysis of kidney cancer (29,020 cases and 835,670 controls), we identified 63 susceptibility regions (50 novel) containing 108 independent risk loci. In analyses...
5.
Perdomo S, Abedi-Ardekani B, de Carvalho A, Ferreiro-Iglesias A, Gaborieau V, Cattiaux T, et al.
Cell Genom
. 2024 Feb;
4(3):100500.
PMID: 38325367
Large-scale biorepositories and databases are essential to generate equitable, effective, and sustainable advances in cancer prevention, early detection, cancer therapy, cancer care, and surveillance. The Mutographs project has created a...
6.
Vasudev N, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, et al.
J Clin Oncol
. 2023 Nov;
42(3):312-323.
PMID: 37931206
Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase...
7.
Vasudev N, Scelo G, Glennon K, Wilson M, Letourneau L, Eveleigh R, et al.
Clin Cancer Res
. 2023 Feb;
29(7):1220-1231.
PMID: 36815791
Purpose: Patients with resected localized clear-cell renal cell carcinoma (ccRCC) remain at variable risk of recurrence. Incorporation of biomarkers may refine risk prediction and inform adjuvant treatment decisions. We explored...
8.
Wai-Shun Chan V, Osman F, Cartledge J, Gregory W, Kimuli M, Vasudev N, et al.
Eur Radiol
. 2022 Apr;
32(9):5811-5820.
PMID: 35384457
Objective: To compare long-term outcomes and peri-operative outcomes of image-guided ablation (IGA) and laparoscopic partial nephrectomy (LPN). Material And Methods: This is a retrospective cohort study of localised RCC (T1a/bN0M0)...
9.
Wah T, Zhong J, Wilson M, Vasudev N, Banks R
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885149
Further biological understanding of the immune and inflammatory responses following ablation is critical to the rational development of combination ablation-immunotherapies. Our pilot exploratory study evaluated the circulating plasma protein profiles...
10.
Zhong J, Palkhi E, Buckley D, Collinson F, Ralph C, Jagdev S, et al.
Diagnostics (Basel)
. 2021 Aug;
11(7).
PMID: 34359384
: To identify dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters predictive of early disease progression in patients with metastatic renal cell cancer (mRCC) treated with anti-angiogenic tyrosine kinase inhibitors (TKI)....